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Abstract: While intratumour genetic heterogeneity of primary clear cell renal cell carcinoma (ccRCC)
is well characterized, the genomic profiles of metastatic ccRCCs are seldom studied. We profiled the
genomes and transcriptomes of a primary tumour and matched metastases to better understand the
evolutionary processes that lead to metastasis. In one ccRCC patient, four regions of the primary
tumour, one region of the thrombus in the inferior vena cava, and four lung metastases (including one
taken after pegylated (PEG)-interferon therapy) were analysed separately. Each sample was analysed
for copy number alterations and somatic mutations by whole exome sequencing. We also evaluated
gene expression profiles for this patient and 15 primary tumour and 15 metastasis samples from
four additional patients. Copy number profiles of the index patient showed two distinct subgroups:
one consisted of three primary tumours with relatively minor copy number changes, the other of
a primary tumour, the thrombus, and the lung metastases, all with a similar copy number pattern
and tetraploid-like characteristics. Somatic mutation profiles indicated parallel clonal evolution with
similar numbers of private mutations in each primary tumour and metastatic sample. Expression
profiling of the five patients revealed significantly changed expression levels of 57 genes between
primary tumours and metastases, with enrichment in the extracellular matrix cluster. The copy
number profiles suggest a punctuated evolution from a subregion of the primary tumour. This process,
which differentiated the metastases from the primary tumours, most likely occurred rapidly, possibly
even before metastasis formation. The evolutionary patterns we deduced from the genomic alterations
were also reflected in the gene expression profiles.
Keywords: intratumour heterogeneity; metastatic ccRCC; copy number alteration; mutation;
gene expression
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1. Introduction
Kidney cancer is a usually lethal urologic malignancy with an annual mortality rate of 50% and
an annual incidence of 337,000 new cases worldwide [1]. About 30% of all kidney cancer patients have
metastases at the time of diagnosis, and another 30–40% will develop metastases at a later stage [2].
Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer in adults and
metastasizes hematogenously to lungs, bone and liver [3].
Although somatic mutation and RNA expression profiles of primary ccRCC have been extensively
described in the Cancer Genome Atlas project [4], the genomic profiles of metastatic ccRCC have
not been frequently studied in the context of their primary tumours. In the few reported cases, intra
primary tumour and metastasis heterogeneity was identified based on differences in copy number
aberrations (CNAs) [5], single nucleotide variants (SNVs) [5,6] and RNA expression patterns [5,7].
Understanding how molecular (genomic) alterations accumulate during tumour evolution is
important to gain insight into the development of metastasis and might provide clues to more optimal
treatment strategies. As the majority of metastases are thought to establish through hematogenous
dissemination [8], studying venous tumour thrombus samples may reveal the mutations of at least
some of the cancer cells on their road to distant metastasis [9].
In this study, we extensively analysed samples from a unique ccRCC patient for whom nine
samples were available taken from multiple regions of a primary ccRCC tumour, tumour thrombus
reaching inferior vena cava, and four pulmonary metastases from different sites in the lung. We analysed
the pattern of CNAs, SNVs, and gene expression in these samples to interrogate the process of tumour
evolution in this patient. To explore the differences in gene expression among primary ccRCCs and
metastases, we then analysed samples from four additional patients.
2. Results
2.1. Copy Number Profiles of Primary and Metastatic ccRCC
Array comparative genomic hybridization (CGH)-based copy number profiles were generated for
three primary tumour samples (Pr1, Pr3, and Pr4), the inferior vena cava tumour thrombus (VT), and
four lung metastases (M1–M4) of the index patient (Figure 1). All samples had a gain of 5q and a loss
of chromosome 3, a small segment of 2q and 10q. In addition to these consistent aberrations, several
CNAs were present in either a single sample or a subset of the primary tumour samples. We also
observed intermediate copy number states at varying positions in all primary tumour samples, which
was indicative of intra-sample heterogeneity in copy number levels. Clear examples of this were a gain
of chromosome 2 in Pr1 and loss of 1p and chromosome 4 in Pr3. The most striking copy number
differences in the primary tumour samples were observed between Pr1 and Pr3, on the one hand, and
Pr4, on the other. Two different samples of primary tumour, Pr1 and Pr3 showed very similar CNA
patterns. In contrast, Pr4 showed more extensive CNAs that closely resembled the patterns of the VT
and the lung metastases, which shared the loss of 1p, 9 and 13q and the gain of chromosome 7, 12p and
20q as their common feature. The lung metastasis that developed after treatment with pegylated
(PEG)-interferon, M4, was distinct from other metastases by several copy number alterations, most
prominently the loss of 11q.
A phylogenetic tree based on the CNA data (Figure 2) shows a clear separation, with two primary
tumour samples (Pr1 and Pr3) on one branch and the third primary tumour sample (Pr4), VT, and the
metastases samples on the other branch. In agreement with the CNA pattern, Pr4 was most closely
related to M2, whereas the VT was almost identical to M3. Even though we noticed variations in
tumour grade among primary tumours and metastases, we were unable to prove a relationship of
regional tumour grade to specific copy number events.
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Figure 1. Array comparative genomic hybridization (CGH) plots of eight tumour samples from 
ccRCC patient 1 (RC1). The x-axes show the genomic position starting from 1pter until Xqter. The y-
axes indicate the log2 intensity ratio between tumour and reference. Abbreviations: Pr1, primary 
tumour 1; Pr3, primary tumour 3; Pr4, primary tumour 4; VT, inferior vena cava tumour thrombus; 
M1, metastasis 1; M2, metastasis 2; M3, metastasis 3; M4, metastasis 4; G1, tumour grade 1; G2, tumour 
grade 2; G3, tumour grade 3; G4, tumour grade 4. 
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VT, and the metastases samples on the other branch. In agreement with the CNA pattern, Pr4 was 
most closely related to M2, whereas the VT was almost identical to M3. Even though we noticed 
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Figure 1. Array comparative genomic hybridization (CGH) plots of eight tumour samples from ccRCC
patient 1 (RC1). The x-axes show the genomic position starting from 1pter until Xqter. The y-axes indicate
the log2 intensity ratio between tumour and reference. Abbreviations: Pr1, primary tumour 1; Pr3,
primary tumour 3; Pr4, primary tumour 4; VT, inferior vena cava tumour thrombus; M1, metastasis 1;
M2, metastasis 2; M3, metastasis 3; M4, metastasis 4; G1, tumour grade 1; G2, tumour grade 2; G3,
tumour grade 3; G4, tumour grade 4.
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Figure 2. Phylogenetic tree based on copy number alteration (CNA) characteristics from different 
tumour samples of ccRCC patient 1 (RC1). Abbreviations: Pr1, primary tumour 1; Pr3, primary 
tumour 3; Pr4, primary tumour 4; VT, inferior vena cava tumour thrombus; M1, metastasis 1; M2, 
metastasis 2; M3, metastasis 3; M4, metastasis 4. 
We generated B-allele frequency (BAF) plots for all samples, including Pr2, for which we had no 
array CGH data. The BAF plot of Pr2 resembled that of Pr1 and Pr3, indicating a similar CNA pattern 
(Supplementary Materials Figure S1). We then used the BAF plots to determine absolute 
chromosomal copy numbers, and thus, the ploidy of the tumour cells. All metastases showed the 
lowest copy number states for chromosomes 6, 9, and 13 in the array CGH profiles. The BAF data, 
however, indicated an even number of copies for chromosome 13 in Pr4, VT, and the lung metastases 
(Supplementary Materials Figure S1 and Table S1). This suggests that the tumour cells of Pr4, VT, 
and the four lung metastases contained two copies of chromosome 13. The other genomic segments 
with a similar copy number state in the array CGH plots, including chromosome 3 in all samples 
except M4, also represented a copy number state of 2. The BAF plots also indicated that all copies of 
chromosome 3 in Pr4, VT, and the lung metastases originated from the same parental allele. The next 
level in the CNA plots in Pr4, VT, and the metastases should refer to chromosomal segments for 
which three copies were present. Indeed, the BAF plots of the germline variants for chromosomes 8, 
14, and 15 indicated an odd number of copies in the tumour cells in Pr4, VT, and the lung metastases, 
consistent with the presence of three copies. Taken together, these data indicated that Pr1–Pr3 had a 
near diploid genome, while Pr4, VT, and the four lung metastases had a near tetraploid genome.  
2.2. Somatic Mutations Identified in Primary and Metastatic ccRCC  
Whole exome sequencing (WES) was conducted for all tumour samples of RC1 with matched 
normal kidney cortex used as control. The mean target coverage for all samples was 57×, with a 
coverage >10× for 90% of the target region (Supplementary Materials Table S2).  
A total of 146 non-synonymous somatic mutations identified in 138 genes were defined as a 
major clone mutation in at least one tumour sample, adding up to 390 events of major clone mutations 
in nine tumour samples (Figure 3). In an additional 104 instances, these mutations were classified as 
minor clone mutations. Targeted sequencing to validate 27 randomly chosen somatic mutations 
(including both major and minor clone mutations) in nine tumour samples led to a total of 243 
validation events, e.g., genomic positions where a mutation should either be present or absent in a 
Figure 2. Phylogenetic tree based on copy number alteration (CNA) characteristics from different tumour
samples of ccRCC patient 1 (RC1). Abbreviations: Pr1, prim ry tumour 1; Pr3, primary tumour 3; Pr4,
pri ary tumour 4; VT, inferior vena cava tumour thrombus; M1, metastasis 1; M2, metastasis 2; M3,
metastasis 3; M4, metastasis 4.
We generated B-allele frequency (BAF) plots for all samples, including Pr2, for which we had
no array CGH data. The BAF plot of Pr2 resembled that of Pr1 and Pr3, indicating a similar CNA
p ttern (Supplementary Materials Figur S1). We then used the BAF plots to determine absolute
chromosomal copy numbers, and thus, the ploidy of th tumour cells. All metastases showed the
lowest copy number states for chromosomes 6, 9, and 13 in the ar ay CGH profiles. The BAF data,
ho ever, indicated an even numbe of copies for chromosome 13 in Pr4, VT, and the lung metastases
(Supplementary Materials Figure S1 and Tabl S1). This suggests that the tumour cells of Pr4, VT, and
the four lung metast s s contained two copies of chromosome 13. The other genomic s gments with
a similar c py number sta e in the array CGH pl ts, including chr osome 3 in all samples exc pt M4,
also represented a copy number state of 2. The BAF plots also i dicated that all copies of chromosom
3 in Pr4, VT, nd the lung metastases originated fr m the same parent allele. The next level in the
CNA pl ts in Pr4, VT, and the metastases should refer to chromosomal s gments for which three copi s
w re present. Indeed, the BAF plots of the ger line v riants for chromosomes 8, 14, and 15 indicated
an odd number of copies in th tumour cells in Pr4, VT, and the lung m tastases, c nsistent with the
presence of three copies. Take together, thes data indicated that Pr1–Pr3 had a near diploid genom ,
while Pr4, VT, and the four lung metastases had a near t raploid genome.
2.2. Somatic Mutations Identified in Primary and Metastatic ccRCC
Whole exome sequencing (WES) was conducted for all tumour samples of RC1 with matched
normal kidney cortex used as control. The mean target coverage for all samples was 57×, with a coverage
>10× for 90% of the target region (Supplementary Materials Table S2).
A total of 146 non-synonymous somatic mutations identified in 138 genes were defined as a major
clone mutation in at least one tumour sample, adding up to 390 events of major clone mutations in nine
tumour samples (Figure 3). In an additional 104 instances, these mutations were classified as minor
clone mutations. Targeted sequencing to validate 27 randomly chosen somatic mutations (including
both major and minor clone mutations) in nine tumour samples led to a total of 243 validation events,
e.g., genomic positions where a mutation should either be present or absent in a specific sample
(Supplementary Materials Table S3). Coverage in the targeted sequencing data was sufficient for 207
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events. Almost all of the variants, 203 out of 207 (98%), could be validated. The number of major and
minor clone mutations that could be validated by targeted sequencing was similar: 127 out of 129 for
major clone mutations and seven out of eight for minor clone mutations.
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Figure 3. Somatic mutations identified in multiple regions of the primary tumour and metastases
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genes, as highlighted at the bottom of the figure. Abbreviations: Pr1, primary tumour 1; Pr2, primary
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Eighteen of the 146 non-synonymous somatic mutations (12.3%) were shared by all tumour
samples. Among these were mutations in two well-known ccRCC cancer driver genes (VHL and
PBRM1) and in EPHA4, a lung adenocarcinoma driver gene [10]. Fifty-one mutations (35%) were
present in a subset of the primary tumours but not detected in the VT nor in the lung metastases.
This included a mutation in a known ccRCC cancer driver gene, ARID1A. Twenty mutations were
unique for the metastases. We did not observe a clear increase in mutational load consistent with the
evolutionary path reflected by CNA patterns depicted in Figure 2. Two primary tumour samples,
Pr1 and Pr3 clearly separated in one branch of the phylogenetic tree (Figure 2) and had 18 and 10
unique mutations, respectively. For all other samples, the number of unique mutations fell within the
range of 3–6. In Pr4, we identified 10 mutations that were not present in the other primary tumour
regions, of which three (in BLOC1S4, WDFY4, and CUBN) were shared with VT and all lung metastases.
2.3. Gene Expression Profiling of Primary and Metastatic ccRCC Samples
We carried out a gene expression analysis to further explore the relationship between the primary
tumour and the metastases in the index patient (Supplementary Materials Table S4). Unsupervised
hierarchical clustering based on the 500 most variably expressed genes showed a clear distinction
between three of the primary tumour samples (Pr1, Pr2, and Pr3) and the remaining samples, including
Pr4, VT, and the metastases (Figure 4). The four lung metastases clustered separately from VT and Pr4.
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Figure 4. Unsupervised hierarchical clustering of expression profiles generated for ccRCC patient 1 
(RC1). Clustering was based on the 500 genes with the highest variance in gene expression across all 
samples. The respective tumour samples are indicated at the bottom of the graph. For each gene, the 
mean value across the samples was defined. Expression levels higher than the mean of all samples 
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Figure 4. Unsupervised hierarchical clustering of expression profiles generated for ccRCC patient 1
(RC1). Clustering was based on the 500 genes with the highest variance in gene expression across
all samples. The respective tumour samples are indicated at the bottom of the graph. For each gene,
the mean value across the samples was defined. Expression levels higher than the mean of all samples
are indicated in red. Expression levels lower than the mean are indicated in blue. Site of origin and
the tumour grade are indicated by the colours at the top of the figure. The overall similarity between
tumour samples is depicted by the dendrogram at the top of the figure and is based on the measurement
of the Euclidian distance between tumour samples in expressing genes. Abbreviations: Pr1, primary
tumour 1; Pr2, primary tumour 2; Pr3, primary tumour 3; Pr4, primary tumour 4; VT, inferior vena cava
tumour thrombus; M1, metastasis 1; M2, metastasis 2; M3, metastasis 3; M4, metastasis 4; G2, tumour
grade 2; G3, tumour grade 3; G4, tumour grade 4.
To evaluate the performance of gene expression data in visualizing the relationship of primary
tumour segments to the metastases of the same patient, we generated gene expression profiles for
multiple tumour samples of four additional ccRCC patients (Table 1).
Cancers 2019, 11, 812 7 of 13
Table 1. Tumour sample characteristics.
Patient TumourOrigin Tumour Grade (WHO/ISUP 2012)
Metastatic
Site
Method
Applied
G1 G2 G3 G4-epitheloid G4-sarcomatoid G4-rhabdoid
RC1
(pT3bN0M1)
Index patient
4 primary
samples - - 2 1 1 - WES,
Array CGH,
RNAseq
1 vena
thrombus - 1 - - - -
inferior
vena cava
3 metastasis
pre-treatment - - 1 1 1 - lung
1 metastasis
post-treatment - - - - - 1 lung
RC2
(Pt3NoM1)
4 primary
samples - 3 1 - - - RNAseq
5 metastasis
samples - - 3 2 - - brain
RC3
(pT1bN0M1)
4 primary
samples - - 2 2 - - RNAseq
4 metastasis
samples - - - 4 - -
brain,
omentum
RC4
(pT1N0M1)
4 primary
samples - 2 2 - - - RNAseq
3 metastasis
samples - 2 - 1 - - costae
RC5
(pT3N0M1)
3 primary
samples - 3 - - - - RNAseq
3 metastasis
samples - 1 2 - - - lung
Abbreviations: pT, pathological tumour size; N, lymph node involvement; M, metastasis; G, tumour grade (World
Health Organization/International Society Urological Pathology system, 2012); WES, whole exome sequencing;
Array CGH, array comparative genomic hybridization; RNAseq, RNA sequencing.
Unsupervised hierarchical clustering of the most variably expressed genes for each patient indicated
that the most distinct separation was between the primary tumour samples and the metastatic samples
(Supplementary Materials Figure S2). Within the primary and metastatic samples, the dendrogram
branches tended to be further separated based on their regional grades and metastatic sites. In patient RC3,
one primary tumour sample clustered together with the metastases, suggesting its role as the tumour
region responsible for the metastasis, which was similar to what we observed in our index patient.
2.4. Differentially Expressed Genes in Primary Tumours versus Metastatic Tumours
We next identified genes consistently differentially expressed between primary tumours and
metastases of all five patients. As the VT sample of the index patient (RC1) could not be clearly classified
as a primary tumour or a metastasis, this sample was not included. The analysis identified 57 genes with
an absolute fold change > 3 (p < 0.01), 32 of which were upregulated and 25 that were downregulated
in metastases versus the primary tumours (Supplementary Materials Table S5). The Database for
Annotation, Visualization and Integrated Discovery (DAVID) annotation analysis [11] of these genes
showed enrichment for blood micro-particle group (p < 0.009) (CP, FGA, FGB, SERPINA3, and ALB)
and extracellular matrix organization (p < 0.03) (ACAN, COL11A1, DCN, FGA, FGB, LAMA2, and LOX).
All differentially expressed genes that clustered in the blood micro-particle and extracellular matrix
organization groups were upregulated in metastases, except for ALB and ACAN. Although not indicated
as an enriched pathway, seven genes (COL11A1, DCN, FGA, FOSB, SPOCK1, AQP9, and PTGDS) in this
list are related to the epithelial–mesenchymal transition pathway [12–18].
3. Discussion
Application of high-throughput sequencing to multiregional sampled ccRCC has highlighted
a marked degree of intratumoural genomic heterogeneity [6,9], but cases with analysis of multiple
primary tumour subregions and multiple metastases are still relatively rare. We present a metastatic
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ccRCC patient for whom multiple samples of the primary tumour, inferior vena cava, and lung metastases
were available. Tumour grade heterogeneity is seen both in the primary tumour sections and metastases
by haematoxylin and eosin staining. However, we did not observe any significant morphological feature
that differentiated metastasis from primary tumour sections. In contrast, through multiregional sampling
and extensive genomic analysis, we identified the somatic alterations underlying early and late events in
tumour development. We also identified one subclone within the primary tumour that closely matched
the profiles of the metastases and is, therefore, likely to be their origin.
When we looked at the pattern of structural alterations to map tumour evolutionary events, we noted
two distinct groups. One group, consisting of three primary tumour samples, had a near-diploid genome
with few CNAs. The other group, consisting of primary tumour sample Pr4, the vena cava tumour
thrombus (VT), and all lung metastases, had a complex, largely similar, copy number profile with
tetraploid characteristics. We assumed that conversion of a near diploid tumour cell (Pr1–Pr3) to a near
tetraploid state (Pr4) resulted in a tumour–cell lineage with metastatic potential in this patient.
Theoretically, the VT could have acted as a “distribution station” between the primary tumour
subclone with metastatic potential and all other metastases, as has been observed by Turajlic et al [9].
Alternatively, and not surprisingly, the primary tumour subclone could have “sent out” multiple
cancer cells in parallel, and some of these could have formed the venous thrombus while others
metastasized to distant organs, bypassing that thrombus station. Although based on small copy
number differences in the metastases group, M2 most closely resembles Pr4, whereas VT and M3
have virtually identical copy number patterns with their only difference being an intra-sample copy
number heterogeneity for chr11 in M3. Our data, therefore, suggest that the latter scenario was the most
likely one, and Pr4, rather than VT, was the origin of all the metastases we studied. In this scenario,
a number of closely related subclones may all have emerged in the region of Pr4 that resulted in the
slightly different copy number patterns that we observed in VT and M1–M3. The lung metastasis that
developed after treatment of PEG-interferon, M4, featured additional structural alteration in 11q and
more copy number levels than the rest of the metastases. However, all the CNAs that characterize the
metastases were also present in M4. Thus, M4 seemed derived from the same tumour subclone as the
previously developed metastases. The existence of such clones, including very small ones, in different
types of cancer matching the distant metastasis profile, was demonstrated by single-cell sequencing
experiments including some by our group [19].
Compared to the analysis of the copy number changes, the somatic mutation profiles of the
tumours were less informative for reconstructing metastatic origin but did reveal early evolutionary
steps. We did not observe a clear difference in the mutation load between Pr1, Pr2, and Pr3, on the
one hand, and Pr4, VT, and the lung metastasis, on the other. Only 12% of the somatic mutations
were shared between all primary tumour subregions and the metastases. These included mutations in
the well-known ccRCC-specific cancer driver genes VHL and PBRM1, which were, therefore, most
likely involved in the initiation of tumour development in this patient. A low number of shared
mutations between primary tumours and their metastasis was also reported in a study where single
primary tumour samples were compared with a single metastatic sample per patient [20]. We did not
see a gradual increase of mutation load. Instead, both the primary tumour sections and metastases
we analysed show a more-or-less equal number of unique mutations. The presence of these private
mutations might reflect on-going parallel clonal evolution in each of the primary tumour sections
and in metastasis regions [21]. It probably reflects independent clonal evolution after the structural
variations were established in this patient. The combined data suggest punctuated evolution of
structural variations occurred within a short window of time, after which the mutational load of
different parts of the primary tumour and all the individual metastasis further increased independently.
We identified several somatic mutations restricted to the different metastatic sites in the lungs,
but none of these mutations were shared between all lung metastasis sites. This, again, indicates that
metastasis-to-metastasis dissemination of cancer cells, e.g., as seen in prostate cancer [22], did not
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occur in this patient. Instead, all metastases appeared to have originated individually from the
metastasis-resembling region of the primary tumour.
With respect to the mutations that may have facilitated the process of metastasis, we found it
interesting that we observed a missense mutation of ARHGAP12 and a frameshift deletion of CENPN
in the VT and all lung metastatic samples. Gene ARHGAP12 encodes a junctional complex protein
that affects tumour cell adhesion, scattering, and migration driven by hepatocyte growth factor [23,24].
These processes regulate invasive growth, and when aberrantly expressed in cancer cells, leads to
cancer invasion and metastasis [25]. Downregulated ARHGAP12 has been related to the increased
invasive growth of human cancer cell lines from lung epithelial cells, prostate, thyroid, and breast [24].
As it is well known, CENPN is important in kinetochore assembly prior to mitosis [26]. Although
no literature specifically mentions the involvement of these mutated genes in ccRCC, we speculate
that these mutations contributed to metastasis in the index patient. These mutations may already
have been present in the primary tumour, but if so, the number of tumour cells in our sample was
too small for these mutations to be discovered. Few mutations were only present in area Pr4 of the
primary tumour and were shared with VT and all lung metastases, including one missense mutation
of CUBN. Being expressed in several normal epithelial cell types, including those in the kidney, CUBN
encodes a receptor for intrinsic factor-vitamin B12 complexes [27]. Low CUBN expression has been
found by others in venous tumour thrombus and lung metastases, as compared to primary tumours
of ccRCC [28]. The same study found low CUBN expression was associated with poor overall and
cancer-specific survival in ccRCC patients. In our patient’s tumours, we did not observe low CUBN
expression. In fact, none of the genes that showed differential expression between primary tumour and
metastases carried a mutation in any of the tumour samples. Conversely, the mutations that occurred
in these tumours, apparently did not influence mRNA levels of the mutated genes.
To characterize tumour subclones in primary tumours and metastases based on gene expression,
we analysed mRNA profiles of the index patient and four additional ccRCC patients. Through gene
expression profiling, we were able to confirm the putative metastatic seeding subclone in the index
patient. In the additional patients, we succeeded in one case (RC3). Our inability to identify the
putative metastasis-seeding subclone in the other three patients was most likely due to the incomplete
sampling and did not exclude the presence of such a subclone in the primary tumour.
Among the 57 differentially expressed genes in the metastatic versus primary tumour samples, six
extracellular matrix genes were upregulated, and one was downregulated in the metastases. We also
observed upregulation of seven genes related to the epithelial–mesenchymal transition in the metastases,
three of which are part of the extracellular matrix pathway as well. Together with intratumoural hypoxia,
the extracellular matrix has been suggested to play a crucial role in metastasis development [29] through
specific molecular pathways such as the epithelial–mesenchymal transition [30]. Interestingly, upregulation
of extracellular matrix genes in the metastases of RCC patients has recently been described [31], which
supports our observation.
4. Materials and Methods
4.1. Patient Materials
Formalin-fixed paraffin-embedded (FFPE) tissues were collected from four different regions of the
primary tumour, from the venous tumour thrombus and from four metastatic lesions of one ccRCC
patient—the index patient (Figure 5). With the exception of one lung metastasis (M4), all tumours were
removed prior to PEG-interferon therapy.
For four additional ccRCC patients, multiple regions of a primary ccRCC tumour and metastases
were available (Table 1). Haematoxylin and eosin staining was used to grade each tumour sample
histomorphologically according to the WHO/ISUP system 2012 [32,33]. The study was performed
in accordance with the University Medical Center Groningen Medical Ethical Review board (project
number 20190251, approved 4th January 2016) and Dutch ethical guidelines and laws, and complied
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with the regulations stated in the Declaration of Helsinki. The FFPE tissue section and DNA/RNA
isolation are described in the Supplementary Materials Methods.
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Figure 5. Origin of tumour samples. The primary tumour samples were grade 4 (Pr1), grade 3 (Pr2),
grade 4 with sarcomatoid differentiation (Pr4), and grade 3 (Pr3). The venous tumour thrombus of
10 cm length extending to the inferior vena cava was grade 2 (VT). The metastasis in the lingula of
the left lung was grade 4 with sarcomatoid differentiation (M1). The metastasis in the dorsal apex,
the lower lobe of the left lung, was grade 4 (M2). The metastasis in the lateral basal, the lower lobe of
the right lung, had a tumour grade 3 (M3). The metastasis in the upper lobe of the left lung was grade
4 with rhabdoid differentiation and was obtained by lobectomy after PEG-interferon treatment (M4).
The haematoxylin and eosin -stained images were made based on 400× magnification.
4.2. CNA Analysis
For all of the index patient’s tumour samples, array CGH was carried out using 500 ng genomic
DNA from FFPE tumour samples using the Complete Genomic SureTag DNA Enzymatic Labelling
Kit protocol and an OligoaCGH/ChIP-on-Chip Hybridization kit (Agilent, Santa Clara, CA, USA),
according to the manufacturer’s instructions. Normal kidney cortex DNA isolated from FFPE material
from the index patient was used as reference. Labelled DNA samples were hybridized on the Agilent
Microarray, Custom HD-CGH, 4 × 180 K (Agilent, Santa Clara, CA, USA) following the manufacturer’s
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protocol. After scanning of the arrays, data were analysed with Nexus 7.5 software (BioDiscovery,
El Segundo, CA, USA).
4.3. Whole Exome Sequencing
All tumour samples from the index patient were subjected to whole exome sequencing (WES) (Beijing
Genomic Institute, China). Exome capturing and subsequent library preparation were conducted using
100 ng of DNA isolated from FFPE material using SureSelect-All exon V2™ (Agilent, Santa Clara, CA,
USA). The final library was quantified using an Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA).
Paired-end sequencing with 100 bp reads was performed on the Illumina HiSEQ 4000™ (Illumina, San Diego,
CA, USA). Sequencing data were processed using our in-house bioinformatics pipeline (https://github.com/
mmterpstra/molgenis-c5-TumorNormal/tree/459417cc9553fae8c3040953970938860dafdfea), as described
previously. The GATK HaplotypeCaller (downloaded from https://software.broadinstitute.org/gatk/) was
used as variant caller [34]. Variant filtering and somatic mutation identification are described in the
Supplementary Materials Methods. All sequencing data are available in the European Nucleotide Archive
(ENA) repository (accession number PRJEB32862). To evaluate the CNAs identified by array CGH in more
detail, B-allele frequency plots based solely on germline variants were generated for all tumour samples.
4.4. RNA Sequencing
The RNA libraries were prepared for tumour samples from the index patient and four additional
patients using the QuantSeq 3’ mRNA-Seq library prep kit (Lexogen, Vienna, Austria), according to the
protocol for degraded (FFPE) RNA. The enriched libraries were sequenced on the Illumina NextSeq
500 System (Illumina, San Diego, CA, USA). Processing of raw sequence reads and subsequent gene
expression analysis are described in the Supplementary Materials Methods.
5. Conclusions
Copy number alteration and somatic mutation profiling from multi-region sampling of the primary
tumour and metastases facilitates the identification of somatic alterations that underlie early events in
tumour evolution and subsequent events in metastatic development. Gene expression profiling can
reveal additional alterations at the transcriptome level. Together, these techniques may help to further
identify the genomic profiles in primary renal cell cancer and their metastases, with the ultimate goal of
finding patterns that can improve diagnostics and guide clinical management of this severe condition.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/6/812/s1,
Figure S1: B-allele frequency (BAF) plots of all tumour samples of patient RC1, Figure S2: Unsupervised
hierarchical clustering based on the 500 genes with the highest variance in gene expression across samples from
Patient RC2, RC3, RC4, and RC5, Table S1: Minor allele frequency median of normal and all tumour samples of
Patient RC1, Table S2: Whole exome sequencing quality report of Patient RC1, Table S3: Validation of somatic
mutations by targeted sequencing, Table S4: RNA sequencing quality report of five ccRCC patients, Table S5:
Differentially expressed genes primary vs. metastasis groups in five ccRCC patients.
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